These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39227185)

  • 1. Causal effects of lipid-lowering drugs on inflammatory skin diseases: Evidence from drug target Mendelian randomisation.
    Zang C; Li J; Zhang Y; Deng W; Mao M; Zhu W; Chen W
    Exp Dermatol; 2024 Sep; 33(9):e15157. PubMed ID: 39227185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study.
    Gao X; Luo W; Qu L; Yang M; Chen S; Lei L; Yan S; Liang H; Zhang X; Xiao M; Liao Y; Lee AP; Zhou Z; Chen J; Zhang Q; Wang Y; Xiu J
    Eur J Prev Cardiol; 2024 Jul; 31(9):1132-1140. PubMed ID: 38302118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.
    Ding W; Chen L; Xia J; Pei B; Song B; Li X
    Medicine (Baltimore); 2024 May; 103(18):e38010. PubMed ID: 38701318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study.
    Li J; Yang Z; Wang T; Li M; Wu X; Fu X; Yang C; Li Y; Wang X; Lan Z; Li M; Chen S
    BMC Cancer; 2024 May; 24(1):667. PubMed ID: 38822303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
    Miao L; Miao T; Zhang Y; Hao J
    BMC Cancer; 2024 May; 24(1):602. PubMed ID: 38760735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of lipid-lowering drugs with risk of sarcopenia: a drug target mendelian randomization study and meta-analysis.
    Li J; Zang C; Lv H; Xiao Z; Li P; Xiao B; Zhou L
    Hum Genomics; 2024 Jul; 18(1):76. PubMed ID: 38961447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Causal association between lipid-lowering drugs and female reproductive endocrine diseases: a drug-targeted Mendelian randomization study.
    Zhao J; Wang R; Song L; Han H; Wang P; Zhao Y; Zhang Y; Zhang H
    Front Endocrinol (Lausanne); 2023; 14():1295412. PubMed ID: 38027179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
    He JY; Zhang X; Wang K; Lv WQ
    J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
    Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
    PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
    Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
    Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Lipid-Lowering Drugs and Traumatic Subdural Hemorrhage: A Mendelian Randomization Study.
    Chen K; Li H; Chen Y; Huang H; Wei L
    J Integr Neurosci; 2024 Apr; 23(4):76. PubMed ID: 38682216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of lipid-modifying drug targets for autoimmune diseases: insights from drug target mendelian randomization.
    Hu X; Zhang P; Gao Y; Ding WW; Cheng XE; Shi QQ; Li S; Zhu YY; Pan HF; Wang P
    Lipids Health Dis; 2024 Jun; 23(1):193. PubMed ID: 38909219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation.
    Li F; Mei Y; Wu Q; Wu X
    Cardiology; 2024; 149(5):495-501. PubMed ID: 38531334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.
    Zhao SS; Yiu ZZN; Barton A; Bowes J
    JAMA Dermatol; 2023 Mar; 159(3):275-280. PubMed ID: 36696131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between lipid-lowering agents with intervertebral disc degeneration, sciatica and low back pain: a drug-targeted mendelian randomized study and cross-sectional observation.
    Liu C; Chu X; Biao Y; Jin Q; Zhang Y; Gao Y; Feng S; Ma J; Zhang Y
    Lipids Health Dis; 2024 Oct; 23(1):327. PubMed ID: 39358768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic association of lipid and lipid-lowering drug target genes with atopic dermatitis: a drug target Mendelian randomization study.
    Niu Q; Zhang T; Mao R; Zhao N; Deng S
    Sci Rep; 2024 Aug; 14(1):18097. PubMed ID: 39103489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.
    Alghamdi J; Matou-Nasri S; Alghamdi F; Alghamdi S; Alfadhel M; Padmanabhan S
    Int J Neuropsychopharmacol; 2018 Dec; 21(12):1067-1075. PubMed ID: 29986042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function.
    Rosoff DB; Bell AS; Jung J; Wagner J; Mavromatis LA; Lohoff FW
    J Am Coll Cardiol; 2022 Aug; 80(7):653-662. PubMed ID: 35953131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study.
    Cai G; Liu J; Cai M; Shao L
    Lipids Health Dis; 2024 Aug; 23(1):237. PubMed ID: 39090671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
    Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
    Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.